18
May
Reimbursement and pricing of medicines: AIFA’s new rules effective 1 April 2026
AIFA’s updated Guidelines for the compilation of the dossier supporting price‑and‑reimbursement requests became applicable.
18
May
The role of artificial intelligence in drug discovery and development
The application of artificial intelligence to pharmaceutical research represents one of the most significant transformations the sector has experienced in recent decades.
18
May
The Bolar exemption between harmonisation and persistent grey areas: The EU pharma package reform and the Italian perspective
The Bolar exemption was introduced at the European Union level in 2004.
18
May
Investing through Europe’s regulatory overhaul
The European life sciences and healthcare sector is undergoing a transformative regulatory overhaul that will significantly reshape the investment landscape for venture capital and private equity firms.
